---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-045897"
form_type: "8-K"
ticker: "REGN"
cik: "0000872589"
company_name: "REGENERON PHARMACEUTICALS, INC."
filed_at: "2023-04-17T23:59:59+00:00"
generated_at: "2026-06-17T01:41:10.259445+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Regeneron Chair P. Roy Vagelos not to stand for re-election; Schleifer and Yancopoulos named Co-Chairs

## Summary
- Dr. Vagelos will not stand for re-election at June 9, 2023 Annual Meeting; will serve as Chair until then.
- Board plans to elect Leonard S. Schleifer, M.D., Ph.D. and George D. Yancopoulos, M.D., Ph.D. as Co-Chairs.
- Christine A. Poon will become Lead Independent Director effective after the Annual Meeting.
- Dr. Vagelos's decision not due to any disagreement with Regeneron.

## SEC filing metadata
- accession: 0001104659-23-045897
- form_type: 8-K
- ticker: REGN
- cik: 0000872589
- company_name: REGENERON PHARMACEUTICALS, INC.
- filed_at: 2023-04-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/tm2312956d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-045897
- JSON: https://secwatch.observer/filing/0001104659-23-045897.json
- Plain text: https://secwatch.observer/filing/0001104659-23-045897.txt

## Key facts
- Executive change
  P. Roy Vagelos departed as Chair of the Board at REGENERON PHARMACEUTICALS, INC..
  - Action: not stand for re-election
  - Role: Chair of the Board
  source text: Dr. Vagelos will continue to serve as Chair of the Board for the remainder of his term until the conclusion of the 2023 Annual Meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm
- Executive change
  George D. Yancopoulos was elected as Co-Chair of the Board at REGENERON PHARMACEUTICALS, INC..
  - Action: elected
  - Role: Co-Chair of the Board
  source text: the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm
- Executive change
  Leonard S. Schleifer was elected as Co-Chair of the Board at REGENERON PHARMACEUTICALS, INC..
  - Action: elected
  - Role: Co-Chair of the Board
  source text: the Board plans to elect Leonard S. Schleifer, M.D., Ph.D., President and Chief Executive Officer of the Company, and George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of the Company, as Co-Chairs of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm
- Executive change
  Christine A. Poon was appointed as Lead Independent Director at REGENERON PHARMACEUTICALS, INC..
  - Action: designated
  - Role: Lead Independent Director
  source text: and to designate Christine A. Poon as the Lead Independent Director of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/872589/000110465923045897/0001104659-23-045897-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.